Collegium Pharmaceutical Inc (COLL)

Generated: April 15, 2026

✅ Pass

Business Overview

Collegium Pharmaceutical Inc (NASDAQ: COLL) is a specialty pharmaceutical company focused on developing and commercializing extended-release products for chronic pain management and ADHD. It generates revenue primarily from its pain portfolio, including Xtampza ER and Belbuca, and the ADHD product Jornay PM, through net product sales to wholesalers and pharmacies. In FY 2025, total net revenues reached a record $780.6 million, up 24% year-over-year, with pain portfolio sales at $631.7 million and Jornay PM at $148.9 million.^[2]^[1]

Non-Recurring Revenue

No meaningful non-recurring revenue events appear in Collegium's most recent 1–2 fiscal years (FY 2024–2025). Revenue growth stemmed from organic sources: Jornay PM prescriptions grew 20–57% year-over-year, and pain products like Belbuca (up 5–10%) and Xtampza ER (up 2%) showed steady demand without mentions of one-off contracts, asset sales, legal settlements, or licensing windfalls. Q3 2025 net revenues hit $209.4 million (31% YoY growth) and FY 2025 totaled $780.6 million (24% YoY), driven by core portfolio performance and raised guidance, with no distortions noted in earnings releases.^[1]^[2]

Short-Seller & Fraud Risk

No evidence exists of significant short-seller reports, fraud accusations, accounting irregularities, regulatory investigations, or securities class-action lawsuits targeting Collegium. Search results show no mentions of negative campaigns from short-selling firms. Short interest data is unavailable in provided sources, but the absence of "battleground stock" indicators—such as high short interest above 15% of float combined with active shorts—suggests it does not qualify. Recent earnings calls and releases emphasize positive growth without controversy.^[1]^[2]^[7]

Financial Health

Collegium maintains strong balance sheet health with ample liquidity and manageable debt. As of Q4 2025 (ended December 31, 2025), cash, cash equivalents, and marketable securities stood at $386.7 million, up $224 million from year-end 2024, supported by robust operating cash flows (e.g., $78.4 million in Q3 2025).^[1]^[2]^[7] Net leverage ratio was below 1x, indicating low debt burden relative to cash generation. No near-term debt maturities (within 12–24 months), covenant risks, credit downgrades, or distress signals are reported; the company improved debt terms and repurchased $25 million in shares, reinforcing refinancing capacity.^[2]^[7]

Cyclicality Risk

Collegium does not operate in a significantly cyclical industry. As a pharmaceutical firm specializing in prescription extended-release drugs for chronic conditions like pain and ADHD, its business relies on stable, recurring demand from patients and prescribers rather than economic cycles tied to commodities, manufacturing, or consumer spending. Revenue and margins have grown steadily—FY 2025 net revenues up 24% YoY to $780.6 million, adjusted EBITDA up 15% to $460.5 million—without elevated peaks suggesting mean-reversion risk. Growth reflects product durability and Jornay PM expansion, not cyclical booms.^[1]^[2]

No material concerns across non-recurring revenue, short-seller risks, financial health, or cyclicality; the company demonstrates consistent growth, strong liquidity, and stable operations.^[2]

Sources

Featured in MagicDiligence Analysis

Magic Formula Screen - April 22, 2026 April 22, 2026